| Management target | Revenue FY27 |
|---|
| Margins | Shifting from distribution to manufacturing margins to capture higher value. |
|---|---|
| Order book | AUD 202mn OTC supply (7.5yrs); USD 11mn anti-TB contract (4yrs). |
| Demand visibility | Strong visibility from Noumed and CDMO contracts (>50% contracted revenue). |
| Management confidence | High |
Growth
FY26 revenue led by 63% exports; private sector share rose to 81%. CDMO vertical grew 355.6% CAGR (FY23-26).
Outlook
Investing ₹101.8 cr in new injectable and R&D facilities; targeting injectable capacity of 154.66 mn units by April 2027.
Risks
Regulatory bottlenecks for EU-GMP accreditation and transition risk from a distribution to an in-house manufacturing model.
Last quarter's promises, checked
Delivered
- FY26 Revenue INR 381 cr → delivered INR 381 cr (= BEAT)
- FY26 Standalone EBITDA INR 33 cr → delivered INR 33 cr (= BEAT)
- CDMO revenue share >50% → delivered 63% (= BEAT)
Partly delivered
- INR 440 cr Capex completion by FY27 → INR 571 cr planned/ongoing (= PARTIAL)
Investor Presentation filed with BSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹503.95
- Market cap
- ₹2,226 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 107.2×Sector 50.4×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 4.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Earnings Call Transcript: Key Takeaways
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Q1 FY27 Results: Net Profit ₹7.9 Cr, Up 464.3% YoY
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹7.9 Cr · +464.3% YoY
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports transformational FY26 following the Noumed acquisition. Focus shifts from asset building to monetization through vertical integration and expanding the CDMO export business.
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.
Sai Parenterals Q3 FY26 Results: Net Loss of ₹6.7 Cr
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.
- Key figure
- Net loss ₹6.7 Cr